The Biomarker-Dashboard Movement & Over-Testing
Quantified-Self, Whole-Body Scans, and the Risk of Treating the Number Instead of the Person
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Lab tests regulated under CLIA; many panels marketed direct-to-consumer
Reference only. Not medical advice.
What can go wrong
Harms include anxiety, unnecessary biopsies and procedures from incidental findings, radiation or contrast exposure in some imaging, financial cost, and inappropriate treatment (such as testosterone therapy started on a single questionable reading). Direct-to-consumer panels also generate sensitive data subject to the privacy concerns elsewhere in this library.
This is something to take to a clinician. The Atlas can tell you what is known about the biomarker-dashboard movement & over-testing in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The quantified-self and 'biomarker dashboard' movement encourages frequent, broad testing: large blood panels, continuous glucose monitors in non-diabetics, hormone panels, and elective whole-body MRI scans. Marketed as proactive optimization, it carries a well-described clinical downside: over-testing generates false positives, incidental findings ('incidentalomas'), and anxiety, and can trigger cascades of follow-up tests and procedures that carry their own risks. For men's hormonal health specifically, a single testosterone number on a dashboard is easy to over-interpret: testosterone varies by time of day, illness, and assay, and clinical guidelines require repeat morning testing plus symptoms before it means anything. This entry reflects mainstream evidence-based-medicine cautions; it cross-links to the diagnostics topics in the library.
More data points is not the same as more health.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Every test has a false-positive rate; the more tests you run on a healthy person, the more abnormal-looking results you will get by chance alone. Whole-body MRI in asymptomatic people commonly turns up incidental findings, most benign, that nonetheless prompt biopsies, repeat imaging, and worry. Continuous glucose monitors in non-diabetics produce normal physiological swings that can be misread as pathology. The dashboard aesthetic encourages chasing numbers toward arbitrary 'optimal' ranges that are not validated against hard outcomes.
Why a dashboard testosterone reading misleads
Testosterone has a diurnal rhythm (higher in the morning), drops with acute illness, varies between assays, and is reported against population reference ranges that are themselves debated. A consumer who sees one mid-afternoon reading flagged 'low' on a sleek dashboard may pursue testosterone therapy that guidelines would not support, because the standard requires at least two low morning measurements plus consistent symptoms. The dashboard's job is engagement; the clinician's job is to decide whether a number matters.
What people get wrong
Often saidMore testing means catching problems early
ActuallyIn asymptomatic people, broad testing more often produces false alarms and incidental findings than life-saving early catches. Screening benefits are condition-specific and evidence-based, not universal.
Often saidA number outside the 'optimal' range needs fixing
ActuallyMany 'optimal ranges' marketed by optimization brands are not validated against outcomes. Reference ranges and clinical significance differ, and a single out-of-range value often means nothing.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- Do broad 'optimization' panels improve any hard outcome, or mainly engagement and revenue?
- How should incidental findings from elective whole-body MRI be managed and consented?
- Where is the line between proactive screening and harmful over-testing for an individual?
At a glance
- Core problem
- Over-testing yields false positives and incidentalomas
- Whole-body MRI
- High incidental-finding rate; no outcome evidence in healthy people
- Testosterone caveat
- Needs repeat morning testing plus symptoms
- Guideline stance
- USPSTF/Choosing Wisely caution against non-indicated screening
- Evidence grade
- Optimization claims largely unproven
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about The Biomarker-Dashboard Movement & Over-Testing. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
USPSTF and Choosing Wisely guidancevarious
Recommend against non-indicated broad screening in asymptomatic people due to false positives, incidental findings, and downstream harm
Whole-body MRI incidental-findings literaturevarious
Asymptomatic whole-body screening MRI detects incidental findings in a large fraction of people, most benign, frequently triggering further testing
Endocrine Society testosterone guidancevarious
Diagnosis of hypogonadism requires symptoms plus repeated low morning testosterone, not a single value